AGG Partner, Edward A. Marshall, filed an amicus curiae brief on behalf of the American College of Rheumatology before the Federal Circuit Court of Appeals, seeking to affirm a district court’s ruling that an alternative supplier of colchicine, a gout-treatment drug, could come to market despite patent infringement allegations by a competitive drug manufacturer. The amicus filing featured prominently during oral argument before the Federal Circuit on Jan. 9. That afternoon, the Federal Circuit affirmed, paving the way for immediate introduction of the colchicine drug to the market. The American College of Rheumatology has since issued a press release touting AGG’s work in bringing about this result. Please click here to view the press release.